A federal judge has ruled that CVS' purchase of Aetna was legal under antitrust law; the Trump administration announced $1.8 billion in grants to help states and communities combat the opioid epidemic; Johns Hopkins Medicine has launched the first psychedelic research center in the United States.
A federal judge has approved CVS’ purchase of Aetna, agreeing with a Justice Department decision that the merger is legal under antitrust law, Reuters has reported. A government plan announced in October said it would allow the merger on the condition that the health insurer sell its Medicare prescription drug plan business to WellCare Health Plans. Both deals have already closed, and since then, Centene has agreed to acquire WellCare for $15.27 billion. CVS said the judge’s decision reinforced that CVS and Aetna have already merged.
The Trump administration on Wednesday announced that it is awarding $1.8 billion in grants to help combat the opioid epidemic. Approximately $980 million will go to states and some territories to focus on prevention and treatment, including through expanding rural telemedicine, expanding access to overdose reversal drug naloxone, and prevention programs. According to The Wall Street Journal, another $900 million will go to CDC over 3 years in order to help states and communities track overdose data and implement treatment strategies.
Johns Hopkins Medicine has launched the Center for Psychedelic and Consciousness Research, the first of its kind in the country. The center will study substances like LSD and psilocybin for a variety of mental health conditions, including anorexia, addiction, and depression, reported The New York Times. The center was created with $17 million in funding from private donors and a foundation. Some scientists have been exploring the potential of psychedelics and other recreational drugs for psychiatric problems since the early 2000s.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Eliminating Enhanced PTCs Would Have Cascading Economic Impacts, Report Estimates
March 6th 2025Enhanced premium tax credits (PTCs) have made marketplace health insurance more affordable, and eliminating them could have sweeping impacts on consumers and the health care industry, according to a new report.
Read More